Efficacy and Safety of SA58 Nasal Spray in Close Contact With COVID-19 People

• Status: Recruiting
• Trial end date: 2023-03-30
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized, single-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of SA58 nasal spray in close contact with COVID-19 people.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Sinovac Life Sciences Co., Ltd.
• Collaborator: Beijing Ditan Hospital

Criteria

Inclusion Criteria:

• Subjects aged 18 years and above on the day of enrollment;

• Had recent contact with an infected person, and the time of PCR sampling from a positive infected person, or the time of first contact with a positive infected person should not exceed 72 hours;

• The subjects can understand and voluntarily sign the informed consent form;

Exclusion Criteria:

• Previous history of severe allergy or sensitivity to inhalation allergens;

• Women are breastfeeding, pregnant, or planning to become pregnant during the study period;

• Participated in clinical trials of SARS-CoV-2 neutralizing antibody injections within 180 days prior to screening or clinical trials of other drugs within 4 weeks prior to screening;

• Subjects unable to cooperate with nasal spray inhalation;

• Body temperature at baseline (Day 0)>37.0℃;

• Had a severe neurological disorder (epilepsy, convulsions or convulsions) or psychosis, and have a family history of psychosis;

• The researchers determined that the subjects had a serious chronic medical condition that could interfere with the conduct or completion of the study;

• According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.